Trials / Completed
CompletedNCT06354127
DWP450 for Treating Moderate to Severe Glabellar Lines
A Multi-center, Randomized, Double-blind, Positive Drug-controlled Clinical Study to Evaluate the Safety and Efficacy of Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 473 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWP450 | The test drug or control drug is injected on the day of administration. |
| DRUG | Botox® | The test drug or control drug is injected on the day of administration. |
Timeline
- Start date
- 2020-08-12
- Primary completion
- 2020-11-24
- Completion
- 2021-01-25
- First posted
- 2024-04-09
- Last updated
- 2024-04-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06354127. Inclusion in this directory is not an endorsement.